Woo Kyun Bae

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Hye-Seong Park · 1 shared paper, 2025 · strength 0.37
   • Paper Synergistic Anti-Tumor Efficacy of Modified FOLFIRINOX and NK Cell Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers17172785↗
2. Jung Hun Kang · 2 shared papers, 2021 · strength 0.21
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
   • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
3. Jung Hoon Kim · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
4. Dae Young Zang · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
5. Se‐Il Go · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
6. Hyun Woo Lee · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
7. In Gyu Hwang · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
8. Jun Ho Ji · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
9. H.S. Park · 1 shared paper, 2021 · strength 0.10
   • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
10. Choong‐kun Lee · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
11. Hye Jin Choi · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
12. Sung Hee Lim · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
13. Joon Oh Park · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
14. Changhoon Yoo · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.